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Background: Ion beam therapy represents a promising approach to treat prostate cancer, mainly due to its high
conformity and radiobiological effectiveness. However, the presence of prostate motion, patient positioning and
range uncertainties may deteriorate target dose and increase exposure of organs at risk. Spacer gel injected
between prostate and rectum may increase the safety of prostate cancer (PC) radiation therapy by separating the
rectum from the target dose field. The dosimetric impact of the application of spacer gel for scanned carbon ion
therapy of PC has been analyzed at Heidelberg Ion-Beam Therapy Center (HIT).
Materials and methods: The robustness of ion therapy treatment plans was investigated by comparison of two
data sets of patients treated with and without spacer gel. A research treatment planning system for ion therapy
was used for treatment plan optimization and calculation of daily dose distributions on 2 to 9 Computed
Tomography (CT) studies available for each of the 19 patients. Planning and daily dose distributions were analyzed
with respect to target coverage, maximal dose to the rectum (excluding 1 ml of the greatest dose; Dmax-1 ml) and
the rectal volume receiving dose greater than 90% of prescribed target dose (V90Rectum), respectively.
Results: The application of spacer gel did substantially diminish rectum dose. Dmax-1 ml on the treatment planning
CT was on average reduced from 100.0 ± 1.0% to 90.2 ± 4.8%, when spacer gel was applied. The robustness analysis
performed with daily CT studies demonstrated for all analyzed patient cases that application of spacer gel results in a
decrease of the daily V90Rectum index, which calculated over all patient cases and CT studies was 10.2 ± 10.4 [ml] and
1.1 ± 2.1 [ml] for patients without and with spacer gel, respectively.
Conclusions: The dosimetric benefit of increasing the distance between prostate and rectum using spacer gel for PC
treatment with carbon ion beams has been quantified. Application of spacer gel substantially reduced rectal exposure
to high treatment dose and, therefore, can reduce the hazard of rectal toxicity in ion beam therapy of PC. The results
of this study enable modifications of the PC ion therapy protocol such as dose escalation or hypofractionation.
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In the last decade radiotherapy became one of the most
often applied prostate cancer (PC) treatment methods. Sev-
eral studies demonstrated that increased Tumour Control
Probability (TCP) of localized PC can be achieved by dose
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unless otherwise stated.protocol [1-7]. However, the target dose is constrained by
dose limits to the surrounding organs at risk: rectum and
bladder. In addition, inter- and intrafractional anatomy
variations in the target region increase the hazard of
underdosage of prostate and overdosage of surround-
ing tissue, which might result in toxicity of organs at risk.
Increasing target dose is possible by application of motion
mitigation techniques or/and by improvements of ir-
radiation accuracy realized, among others, by application
of conformal treatment techniques, such as Intensity
Modulated Radiation Therapy (IMRT), Image Guided
Radiation Therapy (IGRT) or arc-based therapy techniques.l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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further hypo-fractionation by the PC radiotherapy, mainly
due to the sharper than in photon therapy dose gradients
achieved thanks to the characteristic physical properties of
ions (Bragg peak) [8]. Especially the irradiation of PC with
carbon ion beams is expected to provide higher treatment
efficacy [9,10], since carbons demonstrate increased radio-
biological effectiveness in comparison with photon or
proton irradiation. However, the high conformity of ion
therapy using raster scan technique is challenged by organ
motion that may strongly affect the quality of target irradi-
ation [11]. Due to the finite range of the ions in tissue,
deviations in the target dose may occur as a result of
variations of material density distribution over the particle
path mainly induced by daily target motion and patient
positioning [12].
The challenge of hypo-fractionated prostate treatment
with scanned ion beams is to limit the hazard of motion
induced dose to the most critical organ at risk, rectum.
Currently, in ion therapy, patient positioning is typically
performed by matching of bony anatomy on the co-
planar radiography images [13]. This patient positioning
procedure does not allow to image prostate, rectum and
bladder (no soft tissue contrast) and the exact location
of these organs in relation to femur bones cannot be
controlled on a daily basis. This study confirms findings
made in photon therapy [14], which show that because
of different rectum or bladder filling than by treatment
planning imaging, rectum might be exposed in a single
treatment fraction to the dose substantially higher than
predicted by treatment planning. This situation cannot
be diagnosed without advanced in-room IGRT methods
like tomography imaging offering soft tissue contrast or
radiography imaging applied in combination with injec-
tion of radio-opaque markers to prostate. Even if applica-
tion of in-room tomography imaging would be a standard
(in-room Computed Tomography - CT, Magneto Resonance
Imaging - MRI), the admissible fraction and total radio-
biological dose limit to the rectum for carbon ion therapy
is an open discussion topic and robustness analysis includ-
ing radiobiological effects of ion radiation as well as clin-
ical experience is required [7,10].
For these reasons, the application of hydro-gel distan-
cing prostate and rectum allows also mitigating the prob-
lems described above and decreasing the potential risk
of rectal toxicity by ion beam irradiation of PC. Several
studies quantified dosimetric benefit to rectum due to the
application of spacer gel in photon therapy, possibly allow-
ing higher doses for target [15,16]. First annotation con-
sidering application of spacer gel for proton therapy and
its dosimetric effects was published by Weber [17]. Our
previous preclinical investigations considered the impact
of spacer gel application on treatment planning (TP) with
ion beams and its potential application for in-vivo rangeverification [18]. In that work we demonstrated that
spacer gels do not change their physical properties under
exposure to high doses of ion irradiation and the penetra-
tion depth of ion beams in gel is stable over therapy course
and could be properly predicted by the CT imaging. On
the basis of these findings safety of treatment planning for
ion therapy of PC is guaranteed, which allows reliable dose
distribution calculations necessary for the robustness ana-
lysis presented in this work.
Further, fundamentally different approach of applica-
tion of spacer gel in combination with ion beam therapy
was proposed by Christodouleas et al. [19], who simulated
application of anterior proton beams, as an alternative to
conventional, opposing horizontal beams protocol, typic-
ally applied in the proton therapy. Christodouleas et al.
suggests using spacer gel to spare rectum from the effects
of possible range uncertainties and dose deposition to
the rectum, which are probable by anterior irradiation
due to the varying bladder filling. Approach proposed by
Christodouleas et al. is conditioned by availability of range
verification methods in the clinical routine.
The goal of presented TP study was to investigate the
dosimetric impact of spacer gel application on safety of
daily irradiation of PC with horizontal ion beams in pres-
ence of motion. Treatment plans and daily dose recalcula-
tions performed on CT studies of prostate patients with
and without spacer gel implant were analyzed in order to
investigate robustness of ion beam irradiation when spacer
is applied. This study was a complementary investigation
to Ion Prostate Irradiation (IPI) trial [10] performed at
Heidelberg Ion Beam Therapy Centre (HIT), Heidelberg,
Germany and used its clinically applied TP protocols.
Materials and methods
Patient data
Computed Tomography (CT) studies of patients treated
with photons and ions in Heidelberg were used for the
retrospective analysis. The studies obtained for TP as well
as verification purposes were used for each patient. In
total, 88 CT studies of 9 patients (59 CT studies) treated
in years 2005–2006 in German Cancer Research Center
(DKFZ), Heidelberg, Germany and 10 patients (29 CT
studies) treated at HIT in 2012 were analyzed (Table 1).
Patients treated at DKFZ who did not have spacer gel im-
plant are called in this study No-Spacer-Data and are la-
beled patient #1-#9. Patients treated at HIT who had
spacer gel implant are called in this study Spacer-Data
and are labeled patient #10-#19 (Table 1). The parameters
of the CT scans used to obtain the patient data are speci-
fied in Table 2. In the presented retrospective analysis the
variable number of CT studies between Spacer-Data and
No-Spacer-Data has its reason in a different purpose of
the CT acquisitions. No-Spacer-Data were obtained for
weekly patient position control [20]. The Spacer-Data
Table 1 This table provides number of CT studies including number of slices available per patient for No-Spacer-Data
(patients from DKFZ) and Spacer-Data (patients from HIT)
A No-Spacer-data Spacer-data
B #1 #2 #3 #4 #5 #6 #7 #8 #9 #10 #11 #12 #13 #14 #15 #16 #17 #18 #19
C 7 8 5 6 9 6 6 6 6 2 3 8 2 2 2 2 2 3 3
D 68 65 67 67 36 67 67 67 63 168 446 557 175 156 182 155 156 500 162
68 67 67 67 37 67 67 67 67 75 150 225 75 75 75 75 75 225 75
68 67 68 67 36 67 67 67 47 150 225 225 75
67 67 67 67 60 67 67 67 47 225
67 67 67 67 67 67 67 67 47 225
67 67 67 36 67 67 67 47 225
67 65 49 225
60 49 225
49
A - Data set description, B – Patient number, C- Number of CT studies including TP-CT, D – number of CT slices per CT study (TP CT is bold).
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of one exception, patient #12) with a research purpose of
post treatment ion beam range verification [21].
No-spacer-data
A Single-slice spiral CT scanner Siemens Emotion is lo-
cated in the photon therapy treatment room of DKFZ in
Heidelberg. This “on-rail” CT unit is set 90° apart from
the 6 MV Siemens Primus linear accelerator (Siemens
OCS, Concorde, CA) and is used for daily pre-treatment
patient positioning [20]. The therapy couch is shared by
both devices. CT scans were performed in a treatment
position. The scan slices containing target volume plus
at least 2 cm in cranial and caudal direction were ob-
tained. Prostate patients treated in DKFZ were immobi-
lized using stereotactic frames (wrap-around body cast
and a head mask), which were removed from the images
by setting the Hounsfield Unit (HU) values around the
contour of patient skin to the air HU value (−1024 HU).
Original treatment plans optimized for photons wereTable 2 Scan parameters used for CT data acquisition of
prostate patients
Spacer-data No-Spacer-
data
Sensation
4
Biograph
mCT
Emotions
Integrated current [mAs] 240 255 72-82
Tube output voltage [kV] 120* 110-130
Reconstruction diameter
[mm]
500**
Pixel size [mm] 0.9765 × 0.9765**
Slice distance [mm] 3**
Transversal CT grid
[pixels]
512×512**
Filtered back-projection reconstruction algorithm was used for all reconstructions.
*The same number for two columns. **The same number for three columns.not used in the presented analysis in order to avoid the
HU uncertainties related to performing dose recalcu-
lation on the CT studies obtained with a different CT
scanner than one used for TP. For the study purposes,
new ion therapy treatment plans were optimized on the
basis of obtained daily CT studies. Physician selected CT
study for TP according to applied in the clinic procedure
which require patient coming for CT imaging as well as
during all therapy fractions with empty rectum and full
bladder. Rectum diameter of about 4 cm on the tranver-
sal view on the CT image in the PTV region was consid-
ered as appropriate to select CT study for TP.
HU stability of this data set was proved by evaluation
of the HU values distribution within the Regions of
Interest (ROI) delineated for TP on the clinical patient
data. The admitted variation of average HU value within a
ROI on daily CT study in comparison to the selected ref-
erence TP CT was checked to be within limits allowed by
Quality Assurance (QA) procedure used at HIT. Details of
HU analysis performed for No-Spacer-Data are presented
in the “Additional file 1”.
Spacer-data
Prostate patients treated at HIT, typically, at least one day
prior to CT imaging, got spacer gel (SpaceOAR™ System,
Augmenix Inc., Waltham, MA, US) implanted in the ur-
ology department of University Clinic Heidelberg. Spacer
gel precursors are injected under ultrasound guidance into
potential space between Dennonvilliers’ Fascia and the
frontal rectal wall and polymerize (solidify) within sec-
onds. The additional space created between prostate and
rectum has a volume of about 10–15 ml. More specific in-
formation about application of spacer gel for ion beam
therapy could be found in our previous publication [18].
Prostate patients treated at HIT were immobilized using
ProStep™ System (Elekta AB (Publ), Stockholm, Sweden).
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SIEMENS Sensation 4 installed in the University Clinic in
Heidelberg. The control CT studies were obtained using
Positron Emission Tomography/Computed Tomography
(PET/CT) unit SIEMENS Biograph mCT installed next
door to the ion therapy treatment room. At HIT PET/CT
is dedicated to post-therapeutic PET measurements per-
formed for in-vivo treatment monitoring [21]. Prostate
patients after the therapy course were either shuttled in
the treatment position to the PET room or (having visited
the restroom) were re-positioned on the couch of the
PET/CT device (approximately 15 minutes after the end
of therapy). CT studies obtained for attenuation correction
of PET acquisitions were used for the analysis presented in
this study. The CT unit of the PET/CT device is commis-
sioned for TP, which allows a reliable dose distribution
calculation of treatment plans optimized for the therapy
and applied to the patients at HIT. The stability of the HU
values between TP CT and daily CT images is guaranteed
by the periodic QA procedures.
Registration of CT studies
HIT offers digital X-ray based patient position verification
system for ion beam therapy of prostate patients. The
radiography based image guidance does not provide the
information about dosimetric effect of soft tissue varia-
tions (including influence of spacer gel) and range uncer-
tainties which are the focus of presented investigation. In
order to concentrate on the soft tissue displacements,
maintaining the registration procedure most accurate and
excluding positioning uncertainties from the dosimet-
ric analysis, an automated bony anatomy-based CT study
registration including translations and rotations was per-
formed using Siemens SyngoRT planning software pack-
age (version VA11A). This procedure imitated ideal
ion therapy treatment conditions possible to achieve with
cone beam CT based positioning allowing 3D imaging
with soft tissue contrast. A fine image alignment was add-
itionally performed by a physician, if a rotation of femur
bones occurred in comparison to the TP CT.
For the Spacer-Data, CT studies acquired with the CT
unit of the PET/CT device were registered to the TP CT
studies. For No-Spacer-Data, for each patient physician
selected a representative daily CT from entire data set as
TP CT and remaining images were registered to the se-
lected one. The registered images were re-sampled to the
dimensions of the planning CT cube.
For both data sets different, highly precise immobilization
methods were applied: wrap-around body cast and a head
mask for No-Spacer-Data set and pro-step system for
Spacer-Data set. In this work it was assumed that inde-
pendent on patient immobilization method, possible posi-
tioning inaccuracies could be neglected in the dosimetric
comparison of data sets with and without spacer gel, ifrigid registration of CT studies based on femur bones
matching is applied.
Contour segmentation
The original contours segmented on the TP CT studies
used for TP at HIT were adopted for this work. On TP
CT and daily CT studies of No-Spacer-Data set as well
as on daily CT studies of Spacer-Data set new contours
were segmented according to the clinical protocol of the
IPI study.
All contours were segmented manually on the trans-
versal view of TP CT for each slice individually. Organs
at risk: bladder, rectum and femur bones were contoured
by a medical physicist and controlled and corrected by
physician. Target structures: GTV (prostate), Clinical
Target Volume (CTV), Planning Target Volume (PTV),
and contour of spacer gel (Gel) were delineated by the
physician who additionally used soft tissue information
from fused MRI. According to the protocol of IPI study
CTV was defined as prostate gland (GTV) + 2 mm includ-
ing 2/3 of Seminal Vesicles. PTV was an anisotropic mar-
gin extension around CTV: 5 mm in anterior-posterior
(AP) and superior-inferior (SI) direction and 7 mm in left-
right (LR) direction in CT coordinate system. Margin
extension in the AP and SI direction guarantees CTV
coverage in presence of prostate motion during the therapy.
Since ion therapy of PC is realized at HIT by application
of two opposing horizontal 90° fields, margins extension
in the LR direction guarantees CTV coverage in presence
of range uncertainties caused by the inaccurate patient
positioning.
Treatment plan optimization
In this work, TRiP98 (TReatment planning for Particles)
software package [22-24], developed at GSI for patient
treatment within ion therapy pilot project, was used
for optimization and dose distribution calculations. The
physical beam-model, input data used by TRiP98 for the
TP optimization and dose distribution calculation were
the same as the data used by Siemens Syngo RT, software
clinically used for the TP at HIT [25]. The biological
optimization and dose distribution calculation for carbon
ions were based on the biological model LEM I which was
introduced by Scholz et al. [26,27] and is currently used
for therapy at HIT. The biological optimization with 12C
was performed with 3.3 Gy (RBE) target dose prescribed to
the PTV, two opposing horizontal fields (90°), 3×3 mm
lateral scanning grid, 3 mm water-equivalent iso-energy
slice spacing and multi-field optimization algorithm
working on CT-grid. The original treatment plans ap-
plied for irradiation of the patient at HIT were not used in
this study.
For each patient of Spacer-Data set the TP optimization
was performed with original CT studies clinically used at
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cist. For each patient of No-Spacer-Data set one of daily
CT studies was selected by physician for treatment plan
optimization and target point was defined automatically
by TRiP98 as the centre of mass of PTV volume.
Dose calculation and data analysis
The robustness studies included application of the treat-
ment plans optimized with TRiP98 to the daily CT studies.
The target point and irradiation field previously used for
TP optimization were also used for dose calculations.
In this study the dosimetric impact of application of spa-
cer gel on rectal dose in presence of daily anatomy varia-
tions was evaluated by a comparison of Spacer-Data and
No-Spacer-Data set. The three-dimensional (3D) dose dis-
tributions were quantitatively analyzed using TP parame-
ters extracted on the basis of calculated dose distributions
and the available contours. The TP parameters calcu-
lated from dose volume histograms (DVH) were used for
evaluation according to the protocol of IPI study. If not
specified differently, the values of TP parameters were
presented using the following convention: median valuea)
b)
Figure 1 Patient #2 of No-Spacer-Data set: comparison of the dose di
“worst case” daily CT (right: c,d). The figure shows transversal (a,c) and
contours and dose distributions. Contours of the target (PTV – blue, CTV - r
delineated with the thick lines on the transversal view and dots on th
with thin isodose lines of 30%, 50%, 70%, 95%. Color field was used fo(MD) ± standard deviation (STD). In addition to the quan-
titative analysis one patient of Spacer-Data and No-
Spacer-Data set were selected as the example patients
(Figures 1 and 2).
First, in order to assess the quality of the optimized
TP, the dose distribution calculated for TP CT was ana-
lyzed. The PTV volume receiving the dose higher than
95% of the prescribed target dose (V95PTV), and dose
conformity index defined as ratio of volume of the target
and the volume of the 90% isodose (considered within
and out of the target; CI90PTV) were evaluated to guaran-
tee comparable quality of optimization for all investigated
patients. The impact of application of spacer gel on the
quality of TP optimization was evaluated by checking the
maximal dose in clinically relevant rectal volume (more
than 1 ml, Dmax-1mlRectum). Second, from the daily dose
distributions the daily coverage of the clinical target vol-
ume (V95CTV) and the daily rectal exposure (V90Rectum)
were evaluated as a measure of impact of application of
spacer gel on the patient dosimetry in presence of daily
anatomy variations. The daily distribution of V90Rectum
index was illustrated for each patient using box plots. Red c)
 d)
e) 
stribution calculated for the “best case”, TP CT (left: a,b) and the
saggital (b,d) views. CT studies are overlapped with the segmented
ed) and the organs at risk (rectum – brown, bladder - yellow) are
e saggital view. Dose distributions (dose legend - e) are presented
r the highest dose regions of 95-100% and 100-107%.
a)  c) 
b)  d)
e) 
Figure 2 Patient #10 of Spacer-Data set: comparison of the dose distribution calculated for the “best case”, TP CT (left: a,b) and the
“worst case” daily CT (right: c,d). The figure shows transversal (a,c) and saggital (b,d) views. CT studies are overlapped with the segmented
contours and dose distributions. Contours of the target (PTV – blue, CTV - red) and the organs at risk (rectum – brown, bladder - yellow)
are delineated with the thick lines on the transversal view and dots on the saggital view. In addition, the contour of the spacer gel is delineated
in pink. Dose distributions (dose legend - e) are presented with thin isodose lines of 30%, 50%, 70%, 95%. Color field was used for the highest dose
regions of 95-100% and 100-107%. The comparison of the subfigures described with the same letters on the Figures 1 and 2 allow seeing the
differences resulting from application of spacer gel.
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tends to 50% of the data distribution (between the first
and the third quartile), whiskers extend to the most ex-
treme data point within 75% data range, the remaining
data were marked as outliers with “+”.
Results
In this study, the dosimetric impact of application of
spacer gel in ion therapy was simulated and quantita-
tively evaluated in robustness analysis by analyzing daily
dose distributions calculated for TP CT and daily CT
studies of Spacer-Data and No-Spacer-Data set.
The treatment plans were optimized aiming to keep
coverage of the PTV on the treatment plan similarly for
each patient case. The analyzed data show that MD and
STD of V95PTV index and coverage index (CI90PTV)
calculated on TP CT studies over both data sets are of
96.5 ± 0.6% and 86.5 ± 1.6%, respectively. The V95PTV
index greater than 95% fulfils the optimization condition.The low values of STD for V95PTV and CI90PTV demon-
strate that the dose distribution over the target was opti-
mized for both data sets in the comparable manner, which
is required for reliable robustness analysis. The compari-
son of the dose distributions of the treatment plans (calcu-
lated on the TP CT) for patients with and without spacer
gel shows that the application of spacer gel reduces the
maximal dose to rectum (Dmax-1mlRectum) from 100.0 ±
1.0% to 90.2 ± 4.8%. Further, the rectal volume receiving
the high dose, greater than 90% of prescribe target dose
(V90Rectum), decreases on the treatment plan from 5.9 ±
2.6 ml to 1.0 ± 1.1 ml when spacer gel is applied. The rec-
tal volume receiving dose greater than 70% of prescribe
target dose (V70Rectum) decreases from 12.2 ± 4.7 ml to
7.1 ± 2.2 ml due to the application of spacer gel prior the
therapy.
The robustness analysis performed in this work shows
that application of spacer gel results in decrease of daily
value of V90Rectum index and, therefore, allows an
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course for all analyzed patient cases. Figure 3a and 3b
compare the results of the robustness analysis by means
of distribution of V90Rectum index extracted from daily
3D dose distributions for No-Spacer-Data and Spacer-
Data set. For each patient the lowest value of V90Rectum
index corresponds to the rectal exposure on the TP CT
study. The patients are sorted from the greatest median
V90Rectum index value to the lowest. For the No-Spacer-
Data the maximal median rectal exposure was calculated
for patient #1: V90Rectum = 19.2 ± 18.8[ml]. For Spacer-
Data set the maximal median rectal exposure was calcu-
lated for patient #10: V90Rectum = 6.5 ± 5.1[ml]. V90Rectum
index calculated over all cases is V90Rectum = 10.2 ± 10.4
[ml] and V90Rectum = 1.1 ± 2.1 [ml] for No-Spacer-Data
and Spacer-Data set, respectively. The patient specific(a
(b
Daily 
Figure
TP CT
Figure
Daily image: (wo
Figure 3 (c,d).
TP CT (best cas
Figure 3 (a,b).
Figure 3 Box plots showing the distribution of V90Rectum index for pa
(b). Each box plots corresponds to the single patient case. Green and red a
were selected to be illustrated as the patient examples on the Figures 1 andistributions of V90Rectum index presented here do not
qualitatively differ from other usually investigated DVH
points like V50Rectum, V70Rectum, which indicates that rec-
tum is spared using spacer gel also in the spectrum of
the lower doses. The daily distribution of V95CTV index
indicates that the application of OAR spacer gel does not
affect the coverage of CTV for the TP constraints applied
in this study. The MD of V95CTV is 99.9 ± 2.5% and
99.8 ± 3.2% for No-spacer-Data and Spacer-Data set, and
therefore fulfills the TP requirements in terms of daily tar-
get coverage.
As an example, the transversal and saggital views on
dose distribution calculated on TP CT (“best case”) and
daily dose distributions plotted over corresponding daily
CT study (“worst case”), including the segmented con-
tours are illustrated for patient #2 of No-Spacer-Data set) 
) 
image (worst case). 
 2 (c,d).
 (best case).  
 2 (a,b)
rst case). 
e).  
tients without spacer gel implant (a) and with spacer gel implant
rrow indicates the values of V90Rectum index of these patients, who
d 2.
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The selection criterion for these patients was the great-
est difference between the value of V90Rectum calculated
for the TP CTand for daily CTstudy (indicated on Figure 1).
As illustrated on the selected views on TP CTs ion beams
allow for a highly conformal coverage of PTV (blue) and
CTV (red) in the both patient cases. The application of
the spacer gel (Figure 2, pink) increases the distance be-
tween the CTV (red) and rectum (brown) in such a way
that the high dose fields do not reach the rectal frontal
wall, as one can see comparing transversal CT slices on
Figures 1b and 2b.
As expected, substantial improvement in rectum spar-
ing is visible by comparison of daily dose distributions
calculated for patient that had spacer gel implanted
(Figure 1c,d) in comparison with patient without spa-
cer gel implant (Figure 2c,d). The saggital view on pa-
tient #2 (no spacer gel, Figure 1d) clearly illustrates
that, due to the rectum filling greater than on the TP CT
(Figure 1b), part of the rectum shifts into the high dose
field dedicated for the target volume (prostate) increasing
the dose to the organ at risk. Comparison of the saggital
views illustrated on Figure 2b and 2d shows that distan-
cing prostate and rectum by application of spacer gel pre-
vents deposition of the high dose field to the rectum. The
partial high dose field deposited to the rectum is present
in the region which has not been reached by the spacer
gel (Figure 2d).
Discussion
The presented dosimetric study quantifies the impact of
application of spacer gel on rectum exposure to high
doses during the ion therapy of PC. The treatment plans
and daily dose distributions were evaluated and com-
pared for 88 fully contoured TP and daily CT studies of
two patient data sets (19 patients), with and without spa-
cer gel. Presented analysis performed on the TP CT stud-
ies indicate a substantial reduction of maximal dose to
rectum (Dmax-1mlRectum) from 100.0 ± 1.0% to 90.2 ±
4.8%, when spacer gel is applied. The evaluation of daily
dose distribution shows that daily rectal volume receiving
dose higher than 90% of target dose (V90Rectum) could be
reduced form tens to single milliliters, when spacer gel is
applied. The presented results confirm and quantify our
expectations from pre-clinical investigations on spacer gel
described in [18], which showed that spacer gel has ad-
equate physical properties for ion therapy (range of the
ions in gel are predictable by TP system with unsubstan-
tial error) and according to the previous experience from
photon therapy [15,16], distancing prostate and rectum in
ion therapy of PC helps to spare rectum from high doses.
Our result is in agreement with treatment planning
studies performed by [17], who compared TP techniques
like IMRT, rapid arc and Intensity Modulated ProtonTherapy (IMPT) and reports dosimetric benefit for rec-
tum from application of spacer gel for all these tech-
niques. The simulations performed by [17] did not
include day-to-day effects of prostate motion and patient
positioning but focused only on the dosimetry of TP. In
order to compare Weber’s results of rectum dosimetry
given in relative numbers with outcome of this study
given in the absolute rectal volume values, Weber’s aver-
age rectal volume receiving 50 Gy (V50 Gy, 64% of pre-
scribed target dose) was divided by average rectal
volume calculated over 8 patients analyzed by Weber. It
was observed that V50 Gy index used by Weber de-
creases from 19% to 14% when spacer gel is applied,
which corresponds to reduction of absolute rectal vol-
ume receiving 64% of prescribed dose from 11 to 9 ml
assuming average delineated volume of rectum calcu-
lated over 8 patients of 65 ml (with spacer) and 57 ml
(without spacer). The results of Weber are of the same
order of magnitude as our finding: V70Rectum decreases
for TP CT studies from 12.2 ± 4.7 ml to 7.1 ± 2.2 ml,
when spacer gel is applied. In another study [19] reports
V60Rectum for pencil beam scanning for a single CT data
set to be in range 0-1% when spacer gel is applied, but
does not report contoured rectal volume. Christodouleas
et al. [19] suggests further dosimetric studies with a
greater number of patient data to confirm the hypothesis
of advantage from application of the anterior irradiation
angles with spacer gel in presence of clinically applicable
ion beam range verification methods.
According to recommendation stated in the “Report
on the 4D treatment planning workshop 2013” [13] in
order to guarantee the reliable comparison of the results
of different research groups it is necessary to unify the
evaluated parameters of treatment planning studies. In
the discussed works comparison of the results is limited
due to different TP parameters used for plan evaluation,
patient to patient variations in the contoured regions of
interest and different PTV concepts used for TP. More
specifically, in order to compare the dosimetric results
of TP studies on PC independent on the delineated rec-
tal volume, on the basis of our experiences it is recom-
mended for the similar TP and clinical studies in the
future to use absolute volume of the rectum receiving
certain dose level as a measure of rectal exposure.
First clinical results of application of spacer gel for ra-
diation therapy show reduced hazard of rectal toxicity
[28], which corresponds with the results of our dosimet-
ric analysis. The reduction of daily rectal exposure by
application of spacer gel allows for dose escalation or ap-
plication of hypofractionated treatment protocol in ion
beam therapy [10], as it was already proposed for photon
therapy [28-31]. The results of our robustness analysis
are clinically relevant dosimetric indication to define ad-
missible fraction dose for PC treatment by means of
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dose escalation or hypofractionation treatment protocol,
taking into account the presence of prostate motion, pa-
tient positioning uncertainties and range variations of
ion beam.
Pre-treatment imaging is a clinically applicable approxi-
mation and assumption of the patient anatomy at the
moment of irradiation, even if a single CT study is an
anatomy representation obtained before or after the treat-
ment. Dosimetric analysis of target and rectal dose
based on CT studies include effects related to soft tissue
displacements in target region as well as range and re/
positioning uncertainties and are present for both No-
Spacer-Data and Spacer-Data set. The fundamental limi-
tation of analysis performed in this study is the fact, that
separation of these variables and quantifying their dosi-
metric effects in the patient is not applicable. The results
of presented work based on the analysis of 88 CT studies
demonstrate that the V90Rectum index calculated over all
cases decreases from 10.2 ± 10.4 [ml] for No-Spacer-Data
to V90Rectum = 1.1 ± 2.1 [ml] for Spacer-Data set. Assum-
ing pre-treatment image guidance based on CT data, this
result demonstrates the benefit of application of spacer gel
in presence of soft tissue variations in the target region,
even if random error of inaccurate patient re/positioning
and beam range variations is included.
The outcomes of the robustness analysis presented in
this work are based on the dose distribution calculations
performed with TRiP98 treatment planning system
which provides equal results to the clinically applied Sie-
mens Syngo RT (HIT-TPS), Treatment Planning System
(TPS) which is commercially used at HIT. Both TPS use
the same experimental input data [25]. Richter compared
dose distributions calculated with HIT-TPS and with
TRiP98 software package and reports that the mean differ-
ences between dose distributions calculated by HIT-TPS
and TRiP equal zero (STD below 1%) [32]. In the clinical
routine, each TP calculated with HIT-TPS is experimen-
tally verified by dose measurements performed in water
phantom as it was proposed by Karger et al. [33] and re-
ported by Henker et al. [34]. The comparison of TRiP98
and HIT-TPS and experimental verification of patient
data routinely performed for HIT-TPS show clinical rele-
vance of our simulations performed with TRiP98 software
package.
Patient to patient variability of presented results dem-
onstrates that the benefit from application of spacer gel
is patient specific. The application of spacer gel protects
rectum from the high dose, if prostate moves during the
therapy course into the irradiation field. Further, Pinkawa
et al. [35] reports that the application of spacer gel reduces
larger prostate displacements and the distance between
prostate and rectum separated by the spacer gel remains
stable during the therapy course.The human factor like quality of image registration and
contour segmentation process which are part of the clin-
ical routine were not evaluated in this study. The contour-
ing process might have influence on the evaluation of
dose parameters because volume and shape of the seg-
mented contours might vary from observer to observer
[36]. The impact of spacer gel application on daily bladder
exposure was not evaluated in this work and should be a
goal of further analysis.
Conclusions
The application of spacer gel enlarges the distance be-
tween prostate and one of the most critical organs at
risk, rectum, reducing rectal exposure to the high doses
and, therefore, hazard of rectal toxicity during ion ther-
apy of PC. The presented quantification provides results
which could be used as a clinical indication for modifica-
tion of PC radiotherapy protocol by dose escalation or
hypofractionation.
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